The global amino acid metabolism drug market is estimated to grow at a significant CAGR during the forecast period. The rising prevalence of amino acid metabolism disorders such as Argininosuccinic academia, Citrullinemia, Homocystinuria, Phenylketonuria, and Maple syrup urine disease will drive the growth of the global amino acid metabolism drug market. According to the National Centre for Biotechnology Information, the global prevalence of phenylketonuria is 6.002 per 100,000 neonates in 2020. It is the disease caused due to congenital defects in the phenylalanine metabolism, an amino acid, which further leads to irreversible nerve ending. 

Additionally, the rising demand for amino acids from the food, pharmaceuticals, and nutraceuticals industry will also propel the growth of the market. The amino acids such as glutamic acids are prescribed as food supplements to maintain the amino acid balance in the infants.. The major restraining factors for the growth of the market include lack of awareness about amino acid metabolic disorders and higher cost of amino acid supplements. 

Amino acids are the building blocks of the body consists of hydrogen (H), nitrogen (N), oxygen (O), and carbon (C), and others, which further join together to form proteins. There are more than 500 amino acids naturally available, among which only 20 are found in the genetic code of an individual. The disorders in which the body fails to metabolize the amino acids or the problem associated with the uptake of the amino acids is termed as amino acid metabolism disorder. The following conditions are inherited generally and could be lethal if not diagnosed or treated early. There are many amino acid metabolism drugs under the pipeline including SYNB1618 (Synlogic Inc.), CNSA-001 (Censa Pharmaceuticals), HMI-102 (Homology Medicines), BMN 307 (Biomarin Pharmaceuticals), and many more. 

The key players contributing to the growth of the global amino acid metabolism drug market by adopting various strategies such as product launches and developments, mergers and acquisitions, partnerships, and agreements, include Merck KGaA, Novartis AG, Takeda Pharmaceutical Company Ltd., AstraZeneca Plc., Boehringer Ingelheim, KOWA, Kythera, Fuji yakhni, LG Life Science, Mitsubishi Tanabe Pharma. For instance, SYNB1618, by Synlogic, was under the phase 1-2a clinical trial in September 2019. The drug is a novel therapy for the treatment of all patients of Phenylketonuria.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered- 

o By Drug Type

o By Indication

o By Distribution Channel

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape- Merck KGaA, Novartis, Takeda Pharmaceutical, Astra Zeneca, Boehringer Ingelheim, KOWA, Kythera, Fuji yakuhin, LG Life Science, Mitsubishi Tanabe Pharma, among others. 
  

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Amino Acid Metabolism Drug Market-segmentation

By Drug Type

• Arginine
• Folic Acid
• Vitamin B6 & B12
• Thiamine
• Vitamin D
• Betaine
• Carglumic Acid
• Saproterin Dihydrochloride
• Others

By Indication

• Phenylketonuria
• Maple Syrup Urine Disease
• Argininosuccinic Acidemia
• Citrullinemia
• Homocystinuria

By Distribution Channel

• Hospital
• Retail Pharmacy
• Online 
• Others

Global Amino Acid Metabolism Drug Market-segmentation by region